ファーマコビジランス市場：臨床試験フェーズ別、手法タイプ別、サービスプロバイダタイプ別、地域別

世界のファーマコビジランス市場は、2025年に80億3,000万米ドルと推定され、2032年には140億3,000万米ドルに達すると予測され、2025～2032年までの年間平均成長率（CAGR）は8.3%で成長する見込みです。

図.ファーマコビジランス市場シェア（%）、2025年地域別

世界のファーマコビジランス市場は、近年著しい成長を遂げています。ファーマコビジランスは、副作用やその他の薬剤関連問題の検出、評価、理解、予防に関する科学と活動と定義されます。医薬品分子が複雑化し、新しい治療法が市場に導入されるにつれ、販売後の医薬品の安全性を効果的にモニタリングする必要性が高まっています。医薬品の安全性モニタリングを義務付ける厳しい規制の枠組みは、副作用の増加とともに、ファーマコビジランスサービスの需要を世界的に押し上げています。さらに、ジェネリック医薬品市場の拡大と新興地域への臨床検査のアウトソーシングが、ファーマコビジランス市場をさらに押し上げています。

市場力学

世界のファーマコビジランス市場は、医薬品副作用の増加、医薬品承認のための厳格な安全規制、効率的な治療法に対する需要の増加、ジェネリック医薬品の市場拡大によって牽引されています。市販後調査を義務付ける厳しい規制ガイドラインは、ファーマコビジランスサービスの需要を増大させる主要因です。さらに、安全性の問題による医薬品回収の動向の高まりにより、製薬会社はファーマコビジランス業務を専門のサービスプロバイダーに委託せざるを得なくなっています。さらに、先進国におけるジェネリック医薬品市場の拡大は、ファーマコビジランス市場の参入企業に大きな機会を提供しています。しかし、中堅・中小製薬企業の予算上の制約や、地域間の医薬品安全性データの報告の複雑さが、市場参入企業に課題を突きつけています。

本調査の主要特徴

• 本レポートは、世界のファーマコビジランス市場を詳細に分析し、2024年を基準年とした予測期間（2025～2032年）の市場規模（10億米ドル）と複合年間成長率（CAGR%）を提供しています。
• また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案マトリクスについて解説しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域による展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
• 企業ハイライト、製品ポートフォリオ、主要なハイライト、財務実績、戦略などのパラメータに基づいて、世界のファーマコビジランス市場の主要企業をプロファイルしています。
• 本レポートから洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
• 世界のファーマコビジランス市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この産業の様々な利害関係者に対応しています。
• 利害関係者は、世界のファーマコビジランス市場分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• 一貫型機会マップ（COM）

第3章 市場力学、規制、動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• 影響分析
• 市場動向
• 規制シナリオ
• 買収と提携のシナリオ
• 資金調達と投資
• PEST分析
• ポーターの分析

第4章 世界のファーマコビジランス市場-コロナウイルス（COVID-19）パンデミックの影響

• 全体的な影響
• 政府の取り組み
• COVID-19による市場への影響

第5章 世界のファーマコビジランス市場、臨床試験フェーズ別、2020～2032年（10億米ドル）

• イントロダクション
• 前臨床研究
• 臨床検査フェーズI
• 臨床検査フェーズII
• 臨床検査フェーズIII
• 市販後研究またはフェーズIV

第6章 世界のファーマコビジランス市場、手法タイプ別、2020～2032年（10億米ドル）

• イントロダクション
• 自発的報告
• ADR報告の強化
• 対象レポート
• コホートイベントモニタリング
• EHRモニタリング

第7章 世界のファーマコビジランス市場、サービスプロバイダタイプ別、2020～2032年（10億米ドル）

• イントロダクション
• 社内
• 契約アウトソーシング

第8章 世界のファーマコビジランス市場、地域別、2020～2032年（10億米ドル）

• イントロダクション
• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東
• アフリカ

第9章 競合情勢

• 企業プロファイル
  • Accenture
  • Cognizant Technology Solutions
  • Laboratory Corporation of America Holdings（LabCorp）
  • IBM Corporation
  • QuintilesIMS（IQVIA）
  • ICON plc
  • Capgemini
  • ITClinical
  • TAKE Solutions Ltd
  • BioClinica
  • PAREXEL International Corporation
  • Wipro Ltd
  • FMD K&L
  • Linical Accelovance
  • United BioSource Corporation（UBC）
  • PRA Health Sciences
  • ArisGlobal
  • Ennov Solutions Inc

第10章 アナリストの推奨事項

• 隆盛と衰退
• 一貫型機会マップ

第11章 参考文献と調査手法

• 参考文献
• 調査手法

Global Pharmacovigilance Market is estimated to be valued at USD 8.03 Bn in 2025 and is expected to reach USD 14.03 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.3% from 2025 to 2032.

Figure. Pharmacovigilance Market Share (%), By Region 2025

The global pharmacovigilance market has been witnessing significant growth in the recent years. Pharmacovigilance is defined as the science and activities relating to the detection, assessment, understanding, prevention of adverse effects or any other drug-related problems. With the growing complexity of drug molecules and the introduction of novel therapies in the market, there is an increasing need to effectively monitor the safety of drugs post marketing. Stringent regulatory framework mandating drug safety monitoring along with increasing instances of adverse drug reactions is propelling the demand for pharmacovigilance services across the globe. Furthermore, the expanding generics market and outsourcing of clinical trials to emerging regions has further boosted the pharmacovigilance market.

Market Dynamics:

The global pharmacovigilance market is driven by the rising number of adverse drug reactions, stringent safety regulations for drug approval, increasing demand for efficacious therapies, and growing generics market. Stringent regulatory guidelines mandating post marketing surveillance is a key factor augmenting the demand for pharmacovigilance services. Furthermore, rising trend of drug recalls due to safety issues has compelled pharmaceutical companies to outsource their pharmacovigilance activities to specialized service providers. Moreover, increasing generics market in developed countries offer significant opportunities for the pharmacovigilance market players. However, budget constraints of small and midsize pharmaceutical companies and complexity of reporting drug safety data across regions pose challenges to market players.

Key Features of the Study:

• This report provides in-depth analysis of the global pharmacovigilance market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global pharmacovigilance market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Accenture, Cognizant, Laboratory Corporation of America Holdings, IBM Corporation, ArisGlobal, ICON plc., Capgemini, ITClinical, FMD K&L, and IQVIA
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global pharmacovigilance market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pharmacovigilance market

Detailed Segmentation-

• By Clinical Trial Phases
  • Total Knee Replacement
  • Partial Knee Replacement
  • Kneecap Replacement
  • Revision Knee Replacement
• By Type of Method
  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Reporting
  • Cohort Event Monitoring
  • EHR Monitoring
• By Type of Service Provider
  • In-House
  • Contract Outsourcing
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Accenture
  • Cognizant Technology Solutions
  • Laboratory Corporation of America Holdings (LabCorp)
  • IBM Corporation
  • QuintilesIMS (IQVIA)
  • ICON plc
  • Capgemini
  • ITClinical
  • TAKE Solutions Ltd
  • BioClinica
  • PAREXEL International Corporation
  • Wipro Ltd
  • FMD K&L
  • Linical Accelovance
  • United BioSource Corporation (UBC)
  • PRA Health Sciences
  • ArisGlobal
  • Ennov Solutions Incc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Clinical Trial Phases
  • Market Snapshot, By Type of Method
  • Market Snapshot, By Type of Service Provider
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Pharmacovigilance Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Pharmacovigilance Market, By Clinical Trial Phases, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Pre-clinical Studies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Clinical Trial Phase I
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Clinical Trial Phase II
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Clinical Trial Phase III
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Post Marketing Surveillance or Phase IV
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Pharmacovigilance Market, By Type of Method, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Spontaneous Reporting
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Intensified ADR Reporting
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Targeted Reporting
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Cohort Event Monitoring
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• EHR Monitoring
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Pharmacovigilance Market, By Type of Service Provider, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• In-House
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Contract Outsourcing
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Pharmacovigilance Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Clinical Trial Phases, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type of Method, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type of Service Provider, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  • U.S.
  • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Clinical Trial Phases, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type of Method, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type of Service Provider, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Clinical Trial Phases, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type of Method, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type of Service Provider, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Clinical Trial Phases, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type of Method, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type of Service Provider, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Clinical Trial Phases, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type of Method, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type of Service Provider, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Clinical Trial Phases, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type of Method, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type of Service Provider, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

• Company Profiles
  • Accenture
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • Cognizant Technology Solutions
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • Laboratory Corporation of America Holdings (LabCorp)
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • IBM Corporation
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • QuintilesIMS (IQVIA)
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • ICON plc
  • Capgemini
  • ITClinical
  • TAKE Solutions Ltd
  • BioClinica
  • PAREXEL International Corporation
  • Wipro Ltd
  • FMD K&L
  • Linical Accelovance
  • United BioSource Corporation (UBC)
  • PRA Health Sciences
  • ArisGlobal
  • Ennov Solutions Inc

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About Us and Sales Contact